A detailed history of Cwm, LLC transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Cwm, LLC holds 207 shares of ITOS stock, worth $1,494. This represents 0.0% of its overall portfolio holdings.

Number of Shares
207
Previous 206 0.49%
Holding current value
$1,494
Previous $3,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

BUY
$10.09 - $17.97 $10 - $17
1 Added 0.49%
207 $2,000
Q2 2024

Jul 09, 2024

BUY
$10.33 - $18.09 $1,187 - $2,080
115 Added 126.37%
206 $3,000
Q1 2024

Apr 05, 2024

SELL
$9.89 - $13.64 $435 - $600
-44 Reduced 32.59%
91 $1,000
Q4 2023

Feb 01, 2024

SELL
$8.57 - $11.06 $1,885 - $2,433
-220 Reduced 61.97%
135 $1,000
Q3 2023

Oct 11, 2023

BUY
$10.95 - $14.6 $3,230 - $4,307
295 Added 491.67%
355 $4,000
Q2 2023

Aug 03, 2023

BUY
$12.93 - $18.05 $659 - $920
51 Added 566.67%
60 $1,000
Q1 2023

Apr 28, 2023

SELL
$13.02 - $22.62 $1,080 - $1,877
-83 Reduced 90.22%
9 $0
Q4 2022

Feb 01, 2023

BUY
$17.77 - $21.6 $142 - $172
8 Added 9.52%
92 $2,000
Q3 2022

Oct 27, 2022

BUY
$18.6 - $27.25 $1,395 - $2,043
75 Added 833.33%
84 $2,000
Q2 2022

Jul 28, 2022

BUY
$16.57 - $35.1 $149 - $315
9 New
9 $0

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $257M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Cwm, LLC Portfolio

Follow Cwm, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.